Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose vs standard-dose rivaroxaban after total knee arthroplasty
ChiCTR2200063471Phase 4Not yet recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of rivaroxaban in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) (2 arms), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoints: Ultrasound of deep vein of lower extremity, Post-operation symptomatic venous thromboembolism (VTE) events and 3 more. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on ChiCTR2200063471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063471.